Ipsen SA

109,50

26-ноября-24 10:29:55

15 мин. задержка

Акции

-1,55

-1,40%

Сегодняшний диапазон

109,20 - 110,80

ISIN

FR0010259150

Источник

Cboe

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

11 июл 2024 00:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024

09 июл 2024 11:00:00 Источник Nasdaq GlobeNewswire
Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 июл 2024 11:00:00 Источник Nasdaq GlobeNewswire
Half-year statement of IPSEN liquidity agreement - 2024 06 30

08 июл 2024 11:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024

02 июл 2024 11:00:00 Источник Nasdaq GlobeNewswire
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

02 июл 2024 00:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

25 июн 2024 11:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

18 июн 2024 11:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

11 июн 2024 11:00:00 Источник Nasdaq GlobeNewswire
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

10 июн 2024 15:54:20 Источник Nasdaq GlobeNewswire
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform

07 июн 2024 00:00:00 Источник Nasdaq GlobeNewswire
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 июн 2024 11:00:00 Источник Nasdaq GlobeNewswire
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

06 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

05 июн 2024 01:00:00 Источник Nasdaq GlobeNewswire
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan

03 июн 2024 00:00:00 Источник Nasdaq GlobeNewswire
Ipsen announces the launch of an employee shareholding plan

30 май 2024 11:15:00 Источник Nasdaq GlobeNewswire
Annual General Meeting of Ipsen S.A. held on 28 May 2024

28 май 2024 11:00:00 Источник Nasdaq GlobeNewswire
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

28 май 2024 00:00:00 Источник Nasdaq GlobeNewswire
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

07 май 2024 07:55:54 Источник Nasdaq GlobeNewswire
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 май 2024 11:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.